David Schenkein is a General Partner at GV leading the life science investment team. He previously served as CEO of Agios Pharmaceuticals and senior vice president at Genentech.
What David can write
GV writes $10M to $30M+ checks, larger than 97% of firms in the atlas.
Bars: how many firms report each check band. Highlighted: GV.Career
- Millennium Pharmaceuticals · senior vice president of clinical research
- Genentech · senior vice president of clinical hematology/oncology
- Agios Pharmaceuticals · chief executive officer and member of the board of directors
- GV · General PartnerNow
- Agios Pharmaceuticals · chief executive officer
Investments named in public bios
Focus
Education
Also at GV
Partners like David
At firms with a similar stage, sector and check size.
Alert me when GV is active
One email when David's firm raises a fund, adds a partner or shows new activity.
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckQuestions
Who is David Schenkein?
David Schenkein is a General Partner at GV leading the life science investment team. He previously served as CEO of Agios Pharmaceuticals and senior vice president at Genentech.
How much does David Schenkein invest?
David Schenkein invests through GV, which writes checks of $10M to $30M+ at seed, series a, series b.
How do I pitch David Schenkein?
A warm intro from a founder GV backed works best. A short LinkedIn note with one line on traction is the next best route.
What did David Schenkein do before GV?
senior vice president of clinical research at Millennium Pharmaceuticals; senior vice president of clinical hematology/oncology at Genentech; chief executive officer and member of the board of directors at Agios Pharmaceuticals; chief executive officer at Agios Pharmaceuticals.
Last updated 2026-10-15. Is this you? Ask for a correction.